Conduent Named a Major Contender in Everest Group Report

In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing

In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding

In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Telecom

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Retail

Customer expectations have grown exponentially. Companies must deliver seamless, real-time, personalized experiences to meet them. Find out what customers are saying about their experiences in Media

Customer expectations have grown exponentially.Companies must deliver seamless, real-time, personalized experiences to meet them.Find out what customers are saying about their experiences in High Tech

In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved tre

Conduent emerged as a Major Contender in the PEAK Matrix and Everest Group identified Conduent to have well-balanced coverage of the banking space across LOBs, which makes it holistic service provider

In this issue of Clinical Watch, we highlight aspects of Medicaid programs that are affected COVID-19 and suggest prior authorization criteria for a new lipid-lowering drug.

In this issue of Clinical Watch, we discuss COVID-19 and suggest prior authorization criteria for immunotherapy to reduce the severity of allergic reactions to peanuts.